Richard LeBlanc

7PUBLICATIONS
28CO-AUTHORS
Transplantation immunologyGene and molecular therapyRegenerative medicine (incl. stem cells)Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|May 16, 2025
Prognostic value and kinetic patterns of measurable residual disease following tandem autologous/allogeneic transplant in newly diagnosed myeloma patients.

Rafik Terra, Stéphanie Thiant, Jean-Sébastien Claveau

|Apr 25, 2025
Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma.

Andrée-Anne Pelland, Mathilde Dumas, Émilie Lemieux-Blanchard

|Nov 26, 2024
A Phase II, Open-Label Study of Lenalidomide and Dexamethasone Followed by Donor Lymphocyte Infusions in Relapsed Multiple Myeloma Following Upfront Allogeneic Stem Cell Transplant.

Richard LeBlanc, Stéphanie Thiant, Rafik Terra

|Aug 13, 2023
Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis.

Richard LeBlanc, Hira Mian, Donna Reece

|Mar 24, 2022
Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database.

Arleigh McCurdy, Christopher P Venner, Esther Masih-Khan

|Nov 30, 2021
Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II study.

Richard LeBlanc, Imran Ahmad, Rafik Terra

Pageof 2

Frequent Collaborators

3 joint publications

Imran Ahmad

3 joint publications

Jean Roy

2 joint publications

Silvy Lachance

2 joint publications

Esther Masih-Khan